The Latest Media and News on Penn Immunotherapy

In the Media

Carl June: The World's 100 Most Influential People

Carl June, MD, has been named one of TIME's 100 most influential people for his pioneering work in the development of CAR T cell therapy at the Abramson Cancer Center.

12-year-old Emily Whitehead, the first patient to receive the therapy, explains why he is so deserving of this honor.

Read the piece on TIME.com

 

Joe Biden speaks with Meghan McCain about Penn Medicine's CAR-T cell therapy on The View

On ABC's The View, in an emotional interview with Meghan McCain, former Vice President Joe Biden offers hope to those affected by cancer. He discusses the CAR-T cell therapy created at Penn Medicine, saying "There are breakthroughs that are occurring now. And it can happen tomorrow. At the University of Pennsylvania where I teach now, at the Abramson [Cancer] Center, there is a thing called a CAR-T cell. They had a breakthrough with a new drug for child leukemia, and it’s working. There is hope."

Watch the clip:

In the News

• NBC: Breakthrough Treatment Saves Lives of Cancer Patients, featuring patient Bill Ludwig
• New York Times: New Gene Treatment Effective for Some Leukemia Patients
• TIME: FDA Approves First Gene Therapy Treatment For Cancer
• New York Times: F.D.A. Approves First Gene-Altering Leukemia Treatment
• Washington Post:FDA Clears First Gene-altering Therapy — ‘A Living Drug’ — for Childhood Leukemia
• Philadelphia Inquirer: FDA Approves First-ever T-cell Cancer Treatment, Pioneered at Penn, CHOP
• ABC World News Tonight: New Breakthroughs in Cancer Research
• Wall Street Journal: How HIV Became a Cancer Cure
• TIME: Cancer’s Newest Miracle Cure
• TIME: Person of the Year 2016, the CRISPR Pioneers

Most Recent News Releases

• Abramson Cancer Canter Studies Show Promise of Immunotherapy Combinations, Including CAR-T
• FDA Approves Penn's Personalized Cellular Therapy for Advanced Leukemia
• Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas
• Personalized Cell Therapy Combined with Ibrutinib Achieves Complete Remission in High Percentage of CLL Patients
• Immunotherapy with DNA Vaccine Shows Promise for HPV-Related Head and Neck Cancer
• Personalized Cell Therapies Show More Promise in Solid Tumors

Parker Institute Is Helping Penn Accelerate Immunotherapy Research

Penn was one of six top medical institutions chosen to form the Parker Institute for Cancer Immunotherapy. It brings together the top minds in cancer to share ideas and findings. The mission is to accelerate breakthrough immune therapies to turn cancer into a curable disease.

Learn more about the collaboration